NanoPalm Selected by Charles River Laboratories

---

RIYADH, Saudi Arabia – April 29, 2025 – NanoPalm, a Saudi deep-tech biotechnology company pioneering next-generation lipid nanoparticle (LNP) gene delivery systems, has been selected as a founding participant in Charles River Laboratories’ inaugural Advanced Therapy Incubator Program (CIP).

Launched by Charles River in December 2024, the CIP is designed to empower early-stage biotechnology companies with the expertise, infrastructure, and mentorship required to accelerate the development of life-changing therapies. NanoPalm’s inclusion marks a major milestone in its mission to revolutionize in vivo gene therapy using AI-optimized LNPs capable of self-targeting specific organs and cells.

“Being selected for the Charles River Incubator Program marks a significant milestone for NanoPalm as we continue our mission to develop next-generation, accessible gene therapies,” said Dr. Ali Alhasan, Founder and CEO of NanoPalm. “This collaboration will accelerate our ability to translate groundbreaking research into real-world clinical solutions and reflects how Saudi Arabia is transforming the biotech ecosystem to align with Vision 2030.”

NanoPalm’s proprietary platform integrates artificial intelligence with advanced nanomedicine design, creating stable, Self-targeting LNPs that overcome the limitations of traditional delivery systems. The support from Charles River, including access to global facilities, tailored mentorship, and regulatory guidance, will allow NanoPalm to further develop its pipeline targeting rare and genetic diseases.

As part of the program, NanoPalm joins a diverse global cohort of innovators in advanced therapies. This recognition comes as NanoPalm deepens its international collaborations and attracts growing interest from global investors, signaling the MENA region’s rise in biopharma innovation.

This partnership also builds on Charles River’s ongoing collaboration with Lafana Holding, a Saudi investment firm that helped identify and nominate NanoPalm for the incubator—an example of international partnerships shaping the future of life sciences.

About NanoPalm
NanoPalm is a Riyadh-based biotech startup and a spinout from KACST, developing AI-designed lipid nanoparticles for in vivo gene therapies. Focused on transforming clinical trial outcomes through precision drug delivery systems, NanoPalm is pioneering nanomedicines to treat genetic diseases more effectively, accessibly, and safely.

Contact:

Investment Relations
info@nanopalm.ltd
www.nanopalm.ltd